What is Zacks Research’s Forecast for PLX Q2 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Stock analysts at Zacks Research issued their Q2 2026 earnings per share (EPS) estimates for Protalix BioTherapeutics in a research note issued to investors on Thursday, May 14th. Zacks Research analyst J. Vandermosten anticipates that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at $0.14 EPS and FY2027 earnings at ($0.02) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Protalix BioTherapeutics in a research report on Thursday, March 19th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $12.00.

Protalix BioTherapeutics Trading Down 3.5%

NYSE:PLX opened at $1.91 on Tuesday. The company has a market capitalization of $153.89 million, a P/E ratio of -14.69 and a beta of -0.01. Protalix BioTherapeutics has a 12 month low of $1.32 and a 12 month high of $3.19. The business’s 50-day moving average is $2.25 and its 200 day moving average is $2.21.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLX. R Squared Ltd purchased a new stake in Protalix BioTherapeutics during the fourth quarter valued at approximately $26,000. SG Americas Securities LLC purchased a new stake in Protalix BioTherapeutics during the fourth quarter valued at approximately $31,000. Bank of America Corp DE raised its position in Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock valued at $32,000 after purchasing an additional 21,886 shares during the period. Marshall Wace LLP purchased a new stake in Protalix BioTherapeutics during the fourth quarter valued at approximately $34,000. Finally, BNP Paribas Financial Markets raised its position in Protalix BioTherapeutics by 126.5% during the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock valued at $34,000 after purchasing an additional 8,498 shares during the period. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical?stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost?effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high?quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.